Best practices for treating unresectable, locally advanced bladder cancer continue to evolve. Read my thoughts on tailoring treatment based on specific patient and disease characteristics in this setting.
The evolution of immune checkpoint inhibitors for advanced bladder cancer may eventually replace chemotherapy. Read my thoughts on these new agents and how I use them in the clinic.
This Interactive Decision Support Tool will let you compare your choice of therapy for patients with advanced bladder cancer with expert recommendations from Matthew Galsky, MD; Matthew I. Milowsky, MD; Daniel P. Petrylak, MD; Elizabeth R. Plimack, MD, MS; and Jonathan E. Rosenberg, MD.
In this virtual presentation, Elizabeth R. Plimack, MD, MS discusses the clinical rationale and data on the use of immune checkpoint inhibitors for patients with advanced bladder cancer. Afterwards, download the slides and use the treatment decision tool for your practice.
In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the current clinical rationale and most recent data on immune checkpoint inhibitors for patients with advanced bladder cancer. Click here to use our online tool to see how to select optimal therapy for your patients.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.